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Introduction: Zellweger spectrum disorder (PBD-ZSD) is a disease continuum caused by mutations in a subset of
PEX genes required for normal peroxisome assembly and function. They highlight the importance of peroxisomes
in the development and functions of the central nervous system, liver, and other organs. To date, the underlying
bases for the cell-type specificity of disease are not fully elucidated.
Methods: Primary skin fibroblasts from seven PBD-ZSD patients with biallelic PEX1, PEX10, PEX12, or PEX26 mutations
and three healthy donors were transduced with retroviral vectors expressing Yamanaka reprogramming factors.
Candidate induced pluripotent stem cells (iPSCs) were subject to global gene expression, DNA methylation,
copy number variation, genotyping, in vitro differentiation and teratoma formation assays. Confirmed iPSCs
were differentiated into neural progenitor cells (NPCs), neurons, oligodendrocyte precursor cells (OPCs), and
hepatocyte-like cell cultures with peroxisome assembly evaluated by microscopy. Saturated very long chain fatty
acid (sVLCFA) and plasmalogen levels were determined in primary fibroblasts and their derivatives.
Results: iPSCs were derived from seven PBD-ZSD patient-derived fibroblasts with mild to severe peroxisome
assembly defects. Although patient and control skin fibroblasts had similar gene expression profiles, genes
related to mitochondrial functions and organelle cross-talk were differentially expressed among corresponding
iPSCs. Mitochondrial DNA levels were consistent among patient and control fibroblasts, but varied among all
iPSCs. Relative to matching controls, sVLCFA levels were elevated in patient-derived fibroblasts, reduced in
patient-derived iPSCs, and not significantly different in patient-derived NPCs. All cell types derived from donors
with biallelic null mutations in a PEX gene showed plasmalogen deficiencies. Reporter gene assays compatible
with high content screening (HCS) indicated patient-derived OPC and hepatocyte-like cell cultures had impaired
peroxisome assembly.
Conclusions: Normal peroxisome activity levels are not required for cellular reprogramming of skin fibroblasts.
Patient iPSC gene expression profiles were consistent with hypotheses highlighting the role of altered
mitochondrial activities and organelle cross-talk in PBD-ZSD pathogenesis. sVLCFA abnormalities dramatically
differed among patient cell types, similar to observations made in iPSC models of X-linked
adrenoleukodystrophy. We propose that iPSCs could assist investigations into the cell type-specificity of
peroxisomal activities, toxicology studies, and in HCS for targeted therapies for peroxisome-related disorders.* Correspondence: hacia@hsc.usc.edu
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Peroxisomes are dynamic organelles that play critical roles
in metabolic processes required for normal eukaryotic cell
functions [1, 2]. The mammalian peroxisome proteome
can vary according to the tissue, cell type, and physio-
logical conditions [3]. Although the human peroxisomal
proteome is not fully defined, at least 80 human proteins
have been annotated as localizing to peroxisomes [4, 5].
In humans and other mammals, peroxisomal activities
are responsible for the catabolism of branched chain
and very long chain fatty acids, hydrogen peroxide
byproducts of fatty acid oxidation, polyamines, certain
amino acids, and glyoxylate [6]. In addition, they are re-
quired for the biosynthesis of ether-phospholipids, such
as plasmalogens, platelet activating factor (PAF), and
mature bile acids [6–8].
Zellweger spectrum disorder (PBD-ZSD) is a disease
continuum consisting of Zellweger syndrome (ZS), neo-
natal adrenoleukodystrophy (NALD), and infantile Refsum
disease (IRD), which are caused by biallelic defects in any
of 14 PEX genes required for normal peroxisome assembly
[9–11]. Individuals with ZS have profound intellectual dis-
abilities secondary to neuronal migration defects and
hypomyelination, hypotonia, liver dysfunction, and skel-
etal abnormalities, with survival up to 2 years of age
[12, 13]. Nevertheless, the majority of PBD-ZSD patients
have NALD and IRD, milder forms of disease that present
after the newborn period [11]. These individuals typically
show mild to moderate intellectual disabilities, craniofacial
dysmorphism, liver dysfunction, progressive sensorineural
hearing loss, retinopathy, and enamel hypoplasia [11, 14].
Individuals with IRD can survive into adulthood, as exem-
plified by a report in 2011 of a 28-year-old cognitively nor-
mal individual with IRD that manifested as severe visual
and sensorineural hearing loss and enamel disease [15]. In
general, disease severity is associated with the levels of re-
sidual PEX gene function [16].
Cultured skin fibroblasts from PBD-ZSD patients typ-
ically show defects in peroxisome assembly and meta-
bolic functions [17]. As such, they provide a valuable
platform for clinical diagnostics, studying the metabolic
basis of disease, and screening for novel therapeutic
agents [17, 18]. Nevertheless, cell type-specific differ-
ences in peroxisome morphology, number, protein com-
position, and metabolic activities, limit the ability of
patient-derived cultured fibroblasts to model the special-
ized effects that peroxisome dysfunction have on other
cell populations, such as those from central nervous sys-
tem (CNS) and hepatic lineages, more relevant to PBD-
ZSD pathology [3].
Here, we report the generation and characterization of
patient-specific induced pluripotent stem cell (iPSC),
CNS, and hepatocyte-like cell models of mild to severe
PBD-ZSD. Gene expression profiles of patient-specificiPSCs, but not skin fibroblasts, reflected proposed patho-
mechanisms of disease highlighting cross-talk among
multiple organelles. Furthermore, the variation in lipid
abnormalities among patient cell types is consistent
with cell type-specific peroxisomal activity levels. Col-
lectively, our results suggest that iPSCs and their deriva-
tives could provide valuable in vitro model systems to
investigate molecular mechanisms and genetic and en-
vironmental modifiers relevant to peroxisome-related




Primary dermal fibroblast cultures from PBD-ZSD pa-
tients and controls were obtained from the Kennedy
Krieger Institute and Coriell Institute Cell Repositories
(CIRC), respectively. We obtained Johns Hopkins Uni-
versity School of Medicine and University of Southern
California Institutional Review Board approval for hu-
man subject research. HepG2 cells were purchased from
CIRC. All the cells described herein were cultured at 37
°C with 5 % CO2. Human primary dermal fibroblasts
and mitomycin C (Sigma-Aldrich) inactivated mouse
embryonic fibroblasts (iMEFs) were cultured in fibro-
blast medium (DMEM with 10 % fetal bovine serum
(FBS), L-glutamine, penicillin/streptomycin, vitamin solu-
tion, essential and nonessential amino acids (Life Tech-
nologies)), as described [19]. iPSCs were cultured on a
layer of iMEFs in iPSC medium (DMEM:F12 medium
with 20 % KSR, L-glutamine, penicillin/streptomycin, non-
essential amino acids, β-mecaptoethanol and bFGF (Life
Technologies)) as described [20–22].
Primary fibroblasts were transduced twice with a mix-
ture of five retroviruses expressing the human OCT4,
SOX2, KLF4, and C-MYC reprogramming factors and
green fluorescent protein (GFP; to measure transduction
efficiency) as described [20]. After 4 days, cells were
trypsinized and re-plated on iMEF feeders and cultured
in iPSC medium containing 1 mM valproic acid. By 4
weeks, candidate iPSC colonies were manually picked
and clonally expanded. Confirmatory analyses were per-
formed on multiple iPSC colonies from controls and
PBD-ZSD patient donors, as described below and listed
in Additional file 1.
Immunostaining and differentiation assays
Alkaline phosphatase staining and immunostaining ana-
lysis using antibodies against OCT4, NANOG, SOX2,
SSEA4, TRA-1-60, TuJ1, α-SMA, and AFP were per-
formed as described [20]. Embryoid bodies (EBs) were
produced from candidate iPSCs and subjected to
in vitro differentiation assays, as described [20]. iPSCs
were subcutaneously injected to the dorsal flanks of
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which were excised and subjected to histological ana-
lysis, as described [20].
Global gene expression profiling
Total RNA samples were processed, and analyzed on
Affymetrix Human Genome 133A 2.0 or 133 Plus 2.0
GeneChips, as described [19]. The RMA algorithm was
used to generate log2-transformed gene expression
values, and conditional false discovery rates (FDRs) were
determined by the spacings LOESS histogram (SPLOSH)
method using the WebArray platform [23] (Additional
file 2). We performed hierarchical clustering analysis
using Partek Genomics Suite software, conducted Gen-
eOntology (GO) and Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway analyses using WebGestalt
tools [24] and used Ingenuity Pathways Analysis (IPA)
software (Ingenuity Systems) to analyze other functional
relationships. Scaled gene expression scores and .cel files
are available at the National Center for Biotechnology In-
formation (NCBI) Gene Expression Omnibus (GEO) re-
pository [25] under Series Accession Number GSE43996.
Global genetic and epigenetic analysis
Human CytoSNP-12 Infinium HD BeadChips and Geno-
meStudio software (Illumina) were used for genome-
wide single nucleotide polymorphism (SNP) genotyping
and for data filtering and analysis, respectively. Copy
number variation (CNV) analysis was performed using
CNVPartition version 2.4.4 with a confidence threshold
set at 50 and a minimum of 10 SNP probes per CNV re-
gion [26]. Specific PEX gene exons were sequenced
using described protocols [27]. 450K Infinium Methyla-
tion BeadChips (Illumina) and GenomeStudio software
were used for global DNA methylation analysis, as de-
scribed [28, 29]. DNA methylation levels were summa-
rized as β-values ranging from 0 (unmethylated) to 1
(fully methylated). Scaled DNA methylation scores and
.idat files are available at the NCBI GEO repository [25]
under Series Accession Number GSE68134. Confirma-
tory bisulfite DNA sequencing was conducted as de-
scribed [28, 29].
mtDNA analysis
The NovaQUANT Human Mitochondrial to Nuclear
DNA Ratio Kit (EMD Millipore, Darmstadt, Germany)
was used to estimate mtDNA levels in select control and
PBD-ZSD patient-derived fibroblasts and iPSCs accord-
ing to manufacturer’s instructions. All mtDNA measure-
ments were performed in triplicate. Controls provided
by the manufacturers included total DNA isolated from
human 143B cells and human 143B rho zero cells. As
previously discussed [30], rho zero cells are devoid of
mtDNA.Lipid analysis
As previously described [20], we evaluated relative satu-
rated very long chain fatty acid (sVLCFA) levels in cell
lysates by determining the ratio of C26:0-lysophosphor-
ylcholine (C26:LPC) and C22:0-lysophosphorylcholine
(C22:LPC) levels (i.e., C26:0LPC/C22:0LPC) by liquid
chromatography–tandem mass spectrometry (LC-MS/
MS). We report %C26:0LPC as being relative to the total
amount of all lysophosphatidylcholine molecular species
(C26:0, C24:0, C22:0, C20:0, C18:0, C18:1, and C18:2
LPCs) and lyso-platelet activating factor molecular spe-
cies (C16:0-Lyso-PAF, and 1-C18:0-Lyso-PAF) deter-
mined in the same LC-MS/MS analysis. All values are
provided in Additional file 3. We also used liquid LC-
MS/MS to measure 16:0p/20:4, 16:0p/18:1, 18:1p/20:4,
18:0p/20:4 phosphatidylethanolamine (PE) plasmalogen
levels in cell lysates as described in [31]. The ratios of
total PE plasmalogens to total LPC are provided in
Additional file 3.
CNS lineage differentiation
EBs were formed and maintained as described [20] for 4
days, then switched to neural induction medium (NIM)
containing DMEM:F12 medium with 1 % N2, L-
glutamine, penicillin/streptomycin, nonessential amino
acids, and 2 μg/ml heparin (Life Technologies) for 3
days. On day 7, EBs were attached to Matrigel-coated
(BD Biosciences) cell culture plates and maintained in
the same medium for an extra 7 to 10 days for neural
epithelia (NE) induction. Small columnar-like neural ros-
ette structures of NE appeared around day 10 [32, 33].
To initiate motor neuron differentiation, 1 μM retinoic
acid (RA) was added to NIM at day 10. After 5 more
days, the NE rosettes were gently blown off by a 1-ml
pipette and triturated to form motor neuron progeni-
tors/neural spheres by culturing in neural differentiation
medium (NDM) (DMEM:F12 with 1 % N2, 2 % B27, L-
glutamine, penicillin/streptomycin, nonessential amino
acids, 2 μg/ml heparin, 1 μM RA and 100 ng/ml sonic
hedgehog (SHH)) for about 1 month (Life Technolo-
gies)). For terminal motor neuron differentiation, neural
spheres were triturated and attached to laminin-coated
cell culture plates and maintained in NDM with 1 μM
cAMP, 200 μg/ml ascorbic acid and neurotrophic factors
(10 ng/ml each of BDNF, GDNF and IGF1) for up to
7 weeks [32, 33].
To initiate oligodendrocyte differentiation, iPSCs were
detached and resuspended in transition medium contain-
ing 50 % iPSC medium and 50 % glial restrictive medium
(GRM) (DMEM:F12, 2 % B27 (Invitrogen), 25 μg/ml
insulin, 6.3 ng/ml progesterone, 10 μg/ml putrescine,
50 ng/ml sodium selenite, 50 μg/ml holotransferrin,
and 40 ng/ml triiodothyronine (Sigma)) with 5 ng/ml
fibroblast growth factor (FGF2) and 20 ng/ml endothelial
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day 3, unattached EBs were switched to GRM supple-
mented with 20 ng/ml EGF and 5 μM RA for 8 days with
daily media changes. On day 11, yellow spheres were se-
lected, cut to smaller pieces and maintained in GRM sup-
plemented with 20 ng/ml EGF. On day 28, yellow spheres
were again cut to smaller pieces and attached to 1:30 di-
luted growth-factor-reduced Matrigel (BD Biosciences) in
the same medium. After 1 week, the attached cell clusters
were dissociated by incubating in 1x HBSS for 10–15
minutes and attached to poly-L-ornithine/fibronectin
double-coated plates. To expand oligodendrocyte pro-
genitors (OPs), cells were maintained in GRM supple-
mented with 1 % N2, 10 ng/ml FGF2 and 20 ng/ml EGF
(Life Technologies) for 10 days, then switched to GRM
supplemented with PDGF-AA (R&D systems), IGF1
(Peprotech), biotin, and cAMP (Sigma-Aldrich). To ob-
tain terminally differentiated oligodendrocytes (OLs),
cells were maintained in GRM supplemented with 1 %
N2, 50 ng/ml noggin (R&D systems), 5 ng/ml FGF2 and
10 ng/ml EGF for 2–3 days. Afterwards, FGF2 and EGF
were removed from the medium along with the addition
of 1 mM cAMP, 200 nM ascorbic acid (Sigma-Aldrich),
20 ng/ml IGF, GDNF, and CNTF (Peprotech) [34–38].
Hepatocyte lineage differentiation
Hepatic cell lineages were derived following the protocol
of Duan et al. [39, 40] with modifications. Briefly, iPSCs
cultured on matrigel-coated plates with MEF-conditioned
medium were induced into definitive endoderm by
switching to serum-free RPMI 1640 medium (Life Tech)
supplemented with 100 ng/ml Activin A (Peprotech), 2
mM L-glutamine, and 1 % antibiotic-antimycotic for 48
hours. This medium was supplemented with 1 × B27 sup-
plement (Life Tech) and 0.5 mM sodium butyrate (Sigma
Aldrich) for the next 3–6 days. To initiate differentiation,
we treated definitive endodermal cells with 20 ng/ml
FGF4, 20 ng/ml bone morphogenic protein 2 (BMP2) and
20 ng/ml hepatocyte growth factor (HGF) (Peprotech) in
Iscove’s modified Dulbecco’s medium (Gibco) with 20 %
FBS, 2 mM L-glutamine, 0.3 mM monothioglycerol
(Sigma Aldrich), 1 % antibiotic-antimycotic, 1 μM insulin
(Gibco), 0.5 % DMSO and 100 nM dexamethosome
(Sigma-Aldrich) for 10 days. For maturation, we cultured
these cells in hepatocyte culture medium supplemented
with SingleQuots (Lonza Walkerville) with 2 % FBS, 20
ng/ml FGF4, 20 ng/ml hepatocyte growth factor (HGF),
50 ng/ml oncostatin M (R&D Systems), 100 nM dexa-
methasone and 0.5 % DMSO for 6 to 10 days.
Characterization of hepatocyte-like cell cultures
Immunostaining was conducted using the following anti-
bodies: anti-albumin (Thermo Scientific #RB-1925-R2),
anti-AFP (Life Tech #18-0055), anti-HNF4a (Santa Cruz#sc-6556), anti-CYP3A (L-14) (Santa Cruz #sc-30621),
anti-ASGPR (Santa Cruz #sc-13467) and appropriate
FITC- or rhodamine-conjugated secondary antibodies.
Flow cytometry analysis was performed using the FACS
LSRII machine (BD Biosciences). Cells in suspension
were fixed in 2 % paraformaldehyde for 15 minutes and
stained with primary antibodies against ASGPR in 5 %
normal donkey serum at room temperature for 30 mi-
nutes followed by secondary antibodies for 20 minutes.
Control samples were stained with the corresponding
IgG only.
Total RNA samples from flow-sorted ASGPR-positive
candidate hepatocyte-like cells obtained from healthy
(control1) and PBD-ZSD patient (PBD_PEX1ms1 and
PBD_PEX1fs1) donors were processed and analyzed on
Affymetrix Human Genome 133A 2.0 microarrays as de-
scribed in the “Global gene expression profiling” section
above. Scaled gene expression scores are provided in
Additional file 4. In addition, scaled gene expression
scores and .cel files are available at the NCBI GEO reposi-
tory [25] under Series Accession Number GSE69066.
Glycogen storage was evaluated using the Periodic Acid-
Schiff (PAS) Kit (Sigma-Aldrich). The amount of urea se-
creted into the cell culture medium was quantified using the
QuantiChrom Urea Assay Kit (BioAssay Systems). The
amount of human albumin secreted in the supernatant was
determined by the AssayMax Human Albumin ELISA Kit
(Assaypro LLC). Urea production and albumin levels
were normalized to total cell numbers, determined by
counting trypsinized cells with a hemocytometer.
Results
Derivation of iPSCs from control and PBD-ZSD patient
fibroblasts
Cultured primary skin fibroblasts from three healthy
control and seven PBD-ZSD patient donors with muta-
tions in the PEX1, PEX10, PEX12, or PEX26 genes were
transduced with retroviruses expressing the human
OCT4, SOX2, KLF4, and c-MYC reprogramming factors
(Table 1). Patient and control fibroblasts produced iPSC-
like colonies by 2 weeks and TRA-1-60- or TRA-1-81-posi-
tive colonies were clonally expanded after 1 month. We
characterized multiple candidate iPSCs from control and
patients, all showing the appropriate morphology and posi-
tive immunostaining for pluripotency markers (Fig. 1a;
Additional file 5). All control and PBD-ZSD patient-derived
candidate iPSCs could be differentiated in vitro into cells
derived from all three germ layers (Fig. 1b). All three candi-
date iPSCs (one control and two patient-derived) injected
into immune-deficient mice produced teratomas with tis-
sue representative of all three germ layers (Fig. 1c).
In all cases, skin fibroblasts and iPSCs derived from
the same donor had at least 99.9 % concordant SNP ge-
notypes, based on BeadArray data. From these analyses,
Table 1 Skin fibroblast donor information
Current ID Prior ID Description PEX gene mutations PEX gene notes
Control1 AG05838 Healthy female, 36 years Presumed wild type None
Control2 AG09599 Healthy female, 30 years Presumed wild type None
Control3 AG13153 Healthy male, 30 years Presumed wild type None
PBD_PEX1fs1 PBD721 PBD-ZSD patient PEX1 c.2097_2098insT p.I700fs; c.2916delA p.G973fs Two null alleles
PBD_PEX1fs2 PBD702 PBD-ZSD patient PEX1 c.2097_2098insT p.I700fs; 2916delA p.G973fs Two null alleles
PBD_PEX1ms1 PBD615 PBD-ZSD patient Homozygous PEX1 c.2528G>A p.G843D Hypomorphic allelesa
PBD_PEX1ms2 PBD643 PBD-ZSD patient Homozygous PEX1 c.2528G>A p.G843D Hypomorphic allelesa
PBD_PEX10 PBD687 PBD-ZSD patient PEX10 c.337delC p. L113fs; c.890T>C p.L297P Null allele and hypomorphic alleleb
PBD_PEX12c PBD673 PBD-ZSD patient Homozygous PEX12 c.959C>T p.S320F Hypomorphic allelesc
PBD_PEX26 PBD604 PBD-ZSD patient Homozygous PEX26 c.292 C>T p.R98W Hypomorphic allelesd
Prior ID number for control cell lines obtained from Coriell Cell Repositories and PBD-ZSD patient cells obtained from the Kennedy Krieger Institute are provided
aSkin fibroblasts derived from multiple patients with this genotype have a temperature-sensitive peroxisome assembly defect [52]
bSkin fibroblasts derived from this patient have relative sVLCFA levels in the normal range under standard growth conditions [53]. PEX1 c.880A>G p.T294A allele of
unknown significance is also present
cSkin fibroblasts derived from multiple patients with this genotype have relative sVLCFA levels in the normal range under standard growth conditions [54]
dSkin fibroblasts derived from multiple patients with this genotype have a temperature-sensitive peroxisome assembly defect [55]
PBD-ZSD Zellweger spectrum disorder, sVLCFA saturated very long chain fatty acid
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sertions or deletions >10 kb in length) in five PBD-ZSD
patient and four control iPSCs (Additional file 6). Consist-
ent with prior reports involving reprogrammed human
cells [41–43], we detected CNCs in 19/28 (68 %) of the
iPSCs analyzed (Additional file 6). Patient iPSCs retained
the expected PEX gene mutations and control iPSCs
lacked these specific mutations.
Global gene expression and DNA methylation profiles of
patient and control-derived cells
We measured the expression levels of over 18,000 tran-
scripts in iPSCs and skin fibroblasts using microarrays.
Unsupervised hierarchical clustering analyses based on
expression data from the most variably expressed tran-
scripts (Fig. 2a) or iPSC signature genes [44] yielded two
distinct sample clusters comprised entirely of either skin
fibroblast or iPSC samples. In both clusters (Fig. 2a and
Additional file 7), the samples grouped independent of
donor health with robust expression of iPSC signature
genes in all candidate iPSCs analyzed, but not in skin fi-
broblasts. We also examined the DNA methylation levels
of over 485,000 CpG sites in genomic DNAs (gDNAs)
from all the fibroblast cultures and iPSCs listed in Table 1.
Hierarchical clustering analysis based on DNA methyla-
tion data from the most highly variable loci produced two
distinct clusters that clearly separated the skin fibroblast
and iPSC gDNA samples, again independent of donor
health (Fig. 2b).
Differentially expressed genes in patient iPSCs reflect
proposed pathogenic mechanisms
No differentially expressed genes (DEGs) (>1.2-fold
change, FDR <0.05) were uncovered based on globalgene expression analysis of skin fibroblasts derived from
six PBD-ZSD patient and three healthy control donors.
In contrast to these observations in fibroblasts, we iden-
tified 132 DEGs (79 with higher and 53 with lower ex-
pression in PBD-ZSD relative to control cells) based on
global gene expression profiles of 13 iPSCs from six
PBD-ZSD patient donors and 12 iPSCs from three
healthy control donors (Additional file 8A). GO analysis
yielded enrichment for “Cellular Component” with cat-
egories that included the endoplasmic reticulum (18
genes), mitochondrion (19 genes), and golgi apparatus
(16 genes) (Additional file 9A). Enriched KEGG path-
ways relevant to peroxisome biology included ‘Fatty Acid
Metabolism’ (Additional file 9D). IPA pathway analyses
highlighted 87 enriched categories that were mostly
broadly defined with two related to carbohydrate me-
tabolism (‘synthesis of carbohydrates’ and ‘uptake of
monosaccharide’) and one related to lipid metabolism
(‘accumulation of lipid’) (Additional file 10E).
Pathway analysis was also conducted on DEGS based
on whether they showed higher expression in PBD-ZSD
patient or control iPSCs. This revealed that most of the
mitochondrial DEGs (13 of 19) and all three HLA-
related DEGS (HLA-E, HLA-F, and HLA-G) showed
higher expression in the peroxisome-deficient patient
iPSCs (Additional file 9B, D, E). IPA pathway analysis
highlighted 58 and 64 categories of DEGS with higher
expression in patient-derived and control iPSCs, respect-
ively. The former included ‘accumulation of lipid’ while
the latter included ‘synthesis of carbohydrates’ and ‘uptake
of monosaccharide’ (Additional file 9E).
We also annotated probe tilings and manually searched
for DEGs relevant to peroxisome biology using the DA-
VID Bioinformatics resource. Although none encoded
AB
C
Fig. 1 Characterization of iPSCs derived from PBD-ZSD patient and healthy control donors. a Alkaline phosphatase (AP) staining and immunostaining
for pluripotency markers in representative healthy control and patient iPSCs. b Immunostaining for cell populations derived from each of the
three germ layers based on in vitro EB differentiation assays conducted on representative healthy control and patient iPSCs. c Teratomas
derived from representative healthy control and patient iPSCs. Teratomas consisted of cell populations representative of all three germ layers.
Scale bar = 50 μm. N neural rosettes; P pigment epithelium; C cartilage tissue; G glandular tissue
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or indirectly related to peroxisomal activities. For example,
ATG12 (higher in patient iPSCs) and KIAA0652 (also
known as ATG13) (higher in control iPSCs) are relevant
to pexophagy, the autophagic degradation of peroxisomes
[45]. PBD-ZSD patient cells can have glycosylphosphatidy-
linositol (GPI) lipid remodeling defects, which results in
the absence of the 1-alkyl-2-acyl form of GPI-anchored
proteins on their surface [46, 47]. Control iPSCs had
higher expression of the PIGL and PGAP2 genes critical
for GPI-anchored protein biosynthesis while patient iPSCs
had higher expression of the THY1 and FOLR1 genes that
encode GPI anchor proteins. DEGS relevant to biochem-
ical activities either directly or indirectly relevant to perox-
isomes included ELOV5, ACAT1, ALDH3A2, CPT1A,
LIPA, and NUDT4 (fatty acid metabolism), CLN8, LIPA,and OSBL2 (cholesterol metabolism), and ACTAT1
(branched chain amino acid metabolism). Splice variants
of the differentially expressed ALDH3A2 gene can yield
peroxisomal or endoplasmic reticulum (ER) proteins [48].
Instability of PEX1-mutated transcripts predicted to be
subject to nonsense-mediated decay
As an internal control to check our sensitivity to detect
DEGs related to peroxisome function, we compared the
gene expression profiles of nine iPSC colonies derived
from all three control donors and four iPSC colonies de-
rived from PBD_PEX1fs1 and PBD_PEX1fs2. These
PBD-ZSD patient-derived colonies should only produce
unstable PEX1 transcripts due to nonsense-mediated
decay. Only 13 DEGs were found in this comparison
(Additional file 8B). In keeping with expectations, PEX1
A B
Fig. 2 Gene expression and epigenetic profiles of fibroblasts and iPSCs. a Dendrogram depicting unsupervised hierarchical clustering analysis of
gene expression data from PBD-ZSD patient and healthy control skin fibroblasts and iPSCs. Analysis was based on log2-transformed gene expression
scores from 575 probe sets with coefficient of variation (CV) greater than 0.25 and conducted using average linkage and Euclidean distance.
Color bar represents log-2 transformed gene expression values. b Dendrogram depicting results of unsupervised hierarchical clustering analysis
of DNA methylation data from PBD-ZSD patient and healthy control skin fibroblasts and iPSCs. Analysis was based on 4073 DNA methylation
assays interrogating autosomal CpG loci with CV greater than 0.75 and the 10th largest and smallest β-value being greater than 0.6 and less
than 0.4, respectively, in order to represent the most variable loci. Clustering was performed using average linkage and Pearson dissimilarity
distance. Color bar represents β-values
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the patient cells. Due to our limited statistical power in
this subset analysis, the numbers of DEGs were too lim-
ited to conduct meaningful pathway enrichment analysis.
Nevertheless, we note that the aforementioned ALDH3A2
gene was a DEG in this analysis.
mtDNA copy number is consistent among fibroblasts but
varies in iPSCs
To further examine the effects of impaired peroxisome as-
sembly on mitochondrial biology, we estimated mtDNA
genome copy number per diploid nuclear genome infibroblasts and iPSCs from patients and controls (Fig. 3).
Normalized estimates of mtDNA genome copy number
were consistent, all within 1.2-fold of one another. In con-
trast, mtDNA genome copy number estimates varied up
to 7.1-fold among iPSCs. Moreover, mtDNA genome copy
numbers varied 2.6-fold between two different iPSC col-
onies derived from healthy donor control1 (Fig. 3).
Derivation and characterization of CNS cell lineages from
control and PBD-ZSD patient fibroblasts
Neural progenitor inductions were performed on six
control and 17 patient iPSC colonies (Additional file 10).
Fig. 3 Estimated mtDNA genome copy number in PBD-ZSD patient and healthy control-derived cells. The numbers of mtDNA genomes per cell
were estimated by quantitative PCR in triplicate. Total DNA isolated from human 143B cells and human 143B rho cells (devoid of mtDNA) served
as positive (+) and negative (−) controls. Fibroblast and iPSC DNA samples were analyzed on different 96-well plates with embedded positive
controls (grey) yielding similar results (330 and 267 mtDNA genomes per cell, respectively). All data from the fibroblast (light blue: controls; dark
blue: patients) and iPSC (light red: controls; dark red: patients) plates were normalized so that internal positive control provided an estimate of 297
mtDNA genomes per cell (average of mtDNA estimates above). Error bars represent the high and low estimates of mtDNA genomes per cell in a
given sample. Fibroblast control4 is derived from fibroblast culture AG04446 obtained from a 48-year-old healthy male donor (Coriell Cell Repositories).
iPSC induced pluripotent stem cell
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we calculated the percentage of attached EBs that
formed neural rosettes. Excluding data from the PEX10
and PEX12 mutant iPSC colonies derived from patient
fibroblasts with relative sVLCFA levels in the normal
range (Additional file 3, discussed in the next section),
the cohort of patient EBs had a 1.8-fold reduced neural
differentiation efficiency relative to control-derived EBs
(P = 0.028) (Additional file 10A). However, there was no
significant difference in the average rates of neural ros-
ette formation from patient- and control-derived EBs, all
ranging from 9 to 13 days (Additional file 10B).
In preliminary studies, we demonstrated that patient
and control iPSCs could be differentiated into Tuj1-
positive neurons and HB9-expressing candidate motor
neurons. Representative immunostaining images acquired
during the neural differentiation process are provided in
Fig. 4 and Additional file 11. There were no obvious mor-
phological differences among the patient- and control-
derived neurons. Patch clamp analysis of a neuron derived
from patient PBD_PEX1fs1 demonstrated electrophysio-
logical characteristics indicative of active sodium channels
and potassium channels (Fig. 4e, f ).
Given their relevance to the pathophysiology of PBD-
ZSD [49, 50], we primarily focused on deriving OL cell
lineages from iPSCs. We demonstrated that patient and
control iPSCs could be differentiated into morphologically
indistinguishable OP cells (OPCs) (Fig. 5a) and passaged a
similar number of times. Two weeks after growth factorwithdrawal, large numbers of healthy control OPCs differ-
entiated into highly branched mature OLs expressing O4
and MBP (Fig. 5b, c). In contrast, patient-derived OPCs
cultured under the same conditions produced a limited
number of small poorly branched O4-positive cells which
could not be maintained as a monolayer of attached cells
(Fig. 5b). Instead, they detached shortly after growth factor
withdrawal and tended to form neural spheres, while
control-derived OLs could be maintained as a monolayer.
Nevertheless, we did observe a small and poorly branched
PBD-ZSD patient-derived OL showing O4- and MBP-
positive staining (Fig. 5c).
Relative sVCLFA and plasmalogen levels in iPSC and CNS
cells from PBD-ZSD patients and controls
To begin to investigate the effects PEX gene mutations
have on lipid catabolism in different cell types, we evalu-
ated the levels of sVLCFAs in patient- and control-
derived fibroblasts, iPSCs, and neural progenitor cells
(NPCs). Consistent with prior reports [51], PBD-ZSD
patient skin fibroblasts cultured in fibroblast growth
media showed elevated sVLCFA levels relative to con-
trols (Table 2, Additional file 3). The magnitudes of the
increases were also consistent with prior knowledge of
the biochemical defect and known or predicted residual
PEX gene functions [52–55]. Since their PEX gene muta-
tions are compatible with normal relative sVCLFA levels
in fibroblasts cultured under standard conditions




Fig. 4 Neural differentiation of PBD-ZSD-derived iPSCs. PDB_PEX1ms1 patient-derived iPSCs were immunostained and imaged during the process
of differentiation into motor neurons. Images depicting the expression of a PAX6 in the neural progenitor cells, b ChAT in neurons, c TuJ1 in neurons,
and d GFP transgene under the control of the HB9 enhancer in transfected motor neurons. e, f Whole cell patch clamp recording from candidate
neurons derived from PBD-ZSD patient PBD_PEX1fs1 iPSCs. e Voltage-clamp records at a single patient cell, showing currents recorded at different
voltages. The shapes of the curves are typical for a cell expressing sodium and potassium channels. Holding potential was −70 mV and the voltages of
the steps range from −60 mV up to +60 mV, in 10-mV steps. f Current-clamp records at a single patient cell in response to current injection. Current
injection triggers action potential firing, as expected for neurons
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remaining group of PBD-ZSD fibroblasts had ≥13.0-fold
increased sVLCFA levels relative to controls (P < 7×10−3
for C26:0LPC/C22:0LPC and %C26:0LPC, see Methods).
Similar results were obtained for patient and control fi-
broblasts cultured in iPSC growth media (Table 2).
Relative sVLCFA levels were significantly reduced in
patient compared to control iPSCs cultured in iPSC
growth media (5.0-fold, P = 0.001); however, differences
in %C26:0LPC did not reach statistical significance
(Table 2, Additional file 3). We did not conduct experi-
ments examining fibroblast growth media due to com-
patibility issues. In our analysis of iPSC-derived cells, we
found no statistically significant differences in the rela-
tive sVLCFA levels of patient- and control-derived NPCs
(Table 2, Additional file 3). There were marked intra-
group fluctuations in relative sVLCFA levels amongNPCs, even among those derived from the same donor.
This could reflect possible cellular heterogeneity within
the NPCs, which were obtained by dissection of neural
rosettes.
We expanded our studies to investigate the effects
PEX gene mutations have on lipid biosynthesis in differ-
ent cell types by determining the relative levels of PE
plasmalogens in all the samples described above. In
agreement with prior reports [51], PBD-ZSD patient skin
fibroblasts with biallelic null mutations in PEX1
(PBD_fs1 and PBD_fs2) grown in fibroblast or iPSC
growth media showed over a threefold average reduction
in relative PE plasmalogen levels compared to controls
(Additional file 3, Student t-test not performed due to
limited sample sizes). The relative PE plasmalogen levels
in the remaining patient skin fibroblasts grown in either
growth media were consistent with prior knowledge
AC
B
Fig. 5 OPCs and mature OLs derived from PBD-ZSD patient and healthy control iPSCs. a Images of OPCs derived from the indicated patient
(top row) and healthy control (bottom row) donor immunostained for the OPC markers, PDGFRα and SOX10. b Images of OLs derived from the
indicated patient and healthy control donors immunostained for O4 without (left) and with (right) bright field staining. c Images of mature OLs
derived from the indicated patient (top row) and healthy control (bottom row) immunostained for myelin basic protein (MBP) and O4 using the
same magnification. Arrows indicate patient cell that is positive for MBP and O4. Blue color represents DAPI nuclear counterstaining in all cases
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nificantly reduced in patient compared to control
iPSCs (3.8-fold, P = 0.01) (Additional file 3). Consistent
with our sVLCFA studies, there were significant intra-
group fluctuations in the relative PE plasmalogen
levels of NPCs, even among those derived from the
same donor.Table 2 Relative saturated very long chain fatty acid levels in cultur
C26:0LPC/C22:0 LPCa
Cell type Mean control Mean patient FCb Pc
Fibroblastd 1.24 16.44 13.3 <3×1
Fibroblaste 0.70 13.96 19.8 <7×1
iPSCf 6.61 1.31 −5.0 0.001
NPCg 7.12 8.25 1.2 0.8
aGeometric means of the indicated ratios are provided. %C26:0LPC relative to the s
of patient to control data. cBased on two-tailed Student t-test of log-transformed da
eCultured in iPSC growth media (three control, five patient samples). fInduced plurip
(NPCs): two control, seven patient samplesDerivation and characterization of hepatocyte-like cells
from control and PBD-ZSD patient fibroblasts
We induced two PBD-ZSD patient and one control
iPSCs into definitive endoderm and hepatocyte-like cell
cultures with similar efficiencies. After completion of the
maturation protocol, hepatocyte-like cell cultures showed
cells with positive immunostaining for albumin, AFP,ed patient- and control-derived cells
%C26:0LPCa
Mean control Mean patient FCb Pc
0−4 0.82 10.33 12.6 <9×10−6
0−3 0.23 3.36 14.3 0.01
0.36 0.11 −3.4 0.07
1.68 1.60 −1.1 0.9
um of all LPCs and Lyso-PAFs measured (see Methods). bFold-change (FC): ratio
ta. dCultured in fibroblast growth media (three control, five patient samples);
otent stem cells (iPSCs): four control, 15 test samples; gNeural progenitor cells
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cells by FACS analysis and conducted microarray-based
global gene expression analysis, which indicated the ro-
bust expression of hepatocyte-like cell markers AFP, ALB,
APOA2, FOXA2, KRT8, KRT18, KRT19, SERPINA1 (also
known as AAT), and TTR (Additional file 4). Nevertheless,
we note that cytochrome P450 gene family members were
poorly expressed in the hepatocyte-like cell cultures de-
rived from both healthy individuals and patients, with the
exception of CYP1B1 which showed moderate to robust
expression (Additional file 4). Although CYP1B1 is not a
specific hepatocyte marker, it has been noted that its in-
duced expression suggests hepatocyte commitment and
maturation [56]. Although immunostaining analysis indi-
cated that the control- and patient-derived cell cultures
were not homogenous, they all contained hepatocyte-like
cells. The presence of hepatocyte-like cells was further
supported by staining for glycogen storage using the PAS
Assay kit (Fig. 6). Moreover, all hepatocyte-like cell cul-
tures produced urea and albumin (Additional file 12).
Patient-derived neural and hepatocyte-like cells show de-
fects in peroxisome assembly
Control- and patient-derived OPCs and hepatocyte-like
cells were transduced with vectors expressing the GFP-
PTS1 reporter protein that is imported into the peroxi-
some matrix in normal human cells, but remains cytosolic
in PBD-ZSD patient cells with peroxisome assembly
defect [18]. In all cases for OPCs and hepatocyte-like
cells, the control cells showed abundant GFP-positive
puncta with the appropriate size (relative to nuclei)Fig. 6 Characterization of iPSC-derived hepatocytes by immunostaining
HNF4a (red), ALB (red), and ASGPR (red) were detected by immunostainin
glycogen storageand distribution consistent with robust peroxisome as-
sembly (Figs. 7 and 8). In contrast, patient-derived cells
all showed cytoplasmic GFP localization that reflects
the peroxisome assembly defect in the donors (Figs. 7
and 8).
Discussion
Although it is known that impaired peroxisome assem-
bly is causally responsible for PBD-ZSD [57–59], the
mechanisms underlying the cell type-specificity of dis-
ease are not fully understood. While most organ systems
are affected, impaired CNS [12, 60, 61] and hepatic cell
functions [62–64] play important roles in disease patho-
genesis and progression. Here, we demonstrate that
PBD-ZSD patient-derived skin fibroblasts with muta-
tions in different PEX genes can be reprogrammed with
similar efficiencies into iPSCs that could be maintained
in culture for prolonged times. These patient-specific re-
sources could provide a gateway to new models to inves-
tigate the cell-type specificity of peroxisome activities
and their roles in the pathophysiology of PBD-ZSD.
To begin to explore their potential applications, we
demonstrated that control- and patient-derived iPSCs
would produce CNS cell types relevant to the etiology of
PBD-ZSD. Despite considerable intra-group variation
consistent with prior reports involving iPSCs derived
from healthy donors [65], there was a statistically signifi-
cant reduction in neural differentiation potency in pa-
tient- relative to control-derived EBs (Additional file
10A). Additional studies are required to confirm these
observations given the large number of variables underand Periodic acid-Schiff staining (PAS). Expression of AFP (green),
g. Blue represents DAPI staining. PAS staining was used to indicate
Fig. 7 Peroxisome assembly in OPCs expressing the GFP-PTS1 reporter gene. Cells were immunostained with antibodies against PGFR-alpha (red)
and nuclei were counterstained with DAPI (blue). As indicated by GFP-positive puncta of appropriate size relative to nuclei, GFP-PTS1 was imported into
peroxisomes in control cells (top row) whereas in the marked PBD-ZSD patient cells (bottom two rows), GFP-PTS1 showed cytoplasmic localization,
reflecting a peroxisome assembly defect. Arrows highlight cells co-expressing PGFR-alpha and GFP-PTS1
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investigated and iPSC passage numbers. In contrast,
the timing of neural rosette formation upon induction
was similar between control- and patient-derived EBs
(Additional file 10B).
Patient-derived iPSCs were capable of differentiating
into a variety of neural cell types, including electrically
active neurons (Fig. 4e, f ). More pertinent to the neuro-
pathogenesis of PBD-ZSD [12], we could generate OPCs
from both patient and control iPSCs; however, it was
considerably more difficult to generate MBP- and O4-
expressing branched mature OLs from PBD-ZSD patient
relative to healthy control cells. The poor branching of
PBD patient-derived O4-positive cells and their inability
to be maintained as a monolayer during differentiation
should be explored in larger-scale studies to determine
definitively if peroxisome dysfunction is casually respon-
sible for these observations.In parallel, we demonstrated that control- and patient-
derived iPSCs are capable of producing hepatocyte-like
cells, which displayed the appropriate protein and gene
expression markers, cell morphology, and ability to store
glycogen (Fig. 6). Moreover, control- and patient-derived
hepatocyte-like cell cultures produced urea and albumin
(Additional file 12). Although our studies were limited,
control- and patient-derived iPSCs showed similar abil-
ities to differentiate into hepatocyte-like cells.
To evaluate peroxisome assembly, we transduced con-
trol- and patient-derived neural precursor and hepatocyte-
like cells with vectors designed to express a GFP-PTS1
reporter protein (i.e., GFP with a C-terminal peroxisome
targeting signal). In keeping with expectations, control-
derived cells showed punctate GFP fluorescence indica-
tive of robust peroxisome assembly, while patient-
derived cells showed diffuse cytoplasmic localization of
the GFP-PTS1 reporter protein indicative of impaired
Fig. 8 Peroxisome assembly in hepatocyte-like cells expressing the GFP-PTS1 reporter gene. Cells were immunostained with antibodies against
ALB (red) and nuclei were counterstained with DAPI (blue). GFP-positive puncta of appropriate size relative to nuclei in control cells (top strip) indicate
peroxisomal import of GFP-PTS1. In the marked patient cells (bottom two rows), GFP-PTS1 had cytoplasmic localization, indicating a peroxisome
assembly defect. Arrows highlight cells co-expressing ALB and GFP-PTS1
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evaluating the localization and abundance of other
peroxisomal proteins in control- and patient-derived
iPSCs, through immunostaining [17] and proteomics
technologies [4, 5], could be of value towards
elucidating the cell type specificity of peroxisome
functions.
In agreement with prior work [66], patient-derived
skin fibroblast cultures had elevated relative sVLCFA
and %C26:LPC levels compared to those from healthy
controls (Table 2). The only exceptions involved cells
from donors PBD_PEX10 and PBD_PEX12, which have
PEX gene mutations that are associated with relative
sVLCFA levels in the normal range in skin fibroblasts
[53, 54] and thus were not considered in iPSC and NPC
lipid data analyses. In contrast, patient-derived iPSCs
had significantly lower relative sVLCFA levels than con-
trols with no statistically significant differences in
%C26:0LPC levels (Table 2). Moreover, there were no
statistically significant differences in the relative sVLCFA
or %C26:0LPC levels in the patient- and control-derived
NPCs analyzed, but possible cellular heterogeneity
within and among NPCs should be taken into consider-
ation when interpreting these results.
It is relevant to compare these biochemical analyses
with those of iPSCs derived from the skin fibroblastsfrom individuals with X-linked adrenoleukodystrophy
(X-ALD) [20, 67], a complex neurological disorder
caused by mutations in the ABCD1 gene that encodes a
peroxisome membrane protein [68–70]. Males with
ABCD1 null mutations have elevated sVLCFA levels in
their blood and urine and reduced sVLCFA catabolic ac-
tivity in their cultured skin fibroblasts, but otherwise
normal peroxisome assembly and metabolic activities.
Similar to our observations involving PBD-ZSD patient-
derived cells, X-ALD patient-derived iPSCs had low rela-
tive sVLCFA levels [20, 67]. Intriguingly, X-ALD iPSCs
can be differentiated into OLs with elevated relative
sVLCFA levels [67]. Our current studies provide add-
itional evidence for the existence of cell type-specific
lipid abnormalities that result from peroxisome dysfunc-
tion. Further studies are needed to determine if these
observations have relevance to the developmental abnor-
malities and/or degenerative conditions found in individ-
uals with PBD-ZSD and other peroxisomal disorders,
such as X-ALD.
As previously discussed [20], cellular sVLCFA levels
are influenced by their rates of biosynthesis and catabol-
ism, rates of cell proliferation, and uptake from culture
medium [67]. We examined the expression levels of
ELOVL gene family members that encode fatty acid
elongating enzymes critical for VLCFA biosynthesis. In
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ELOVL1 family member responsible for the elongation
of C22:0 to C24:0 and C26:0 fatty acids [71, 72] had sig-
nificantly higher expression in fibroblasts relative to
iPSCs, regardless of donor health status. We observed
the differential expression of one ELOVL family member
(ELOVL5), which had a modest 1.4-fold higher expres-
sion in patient relative to control iPSCs (FDR =0.008).
Given that it is involved in the elongation of C18:3, n-6
to C20:3, n-6 and C18:4, n-3 to C20:4, n-3 fatty acids in
mouse liver [73], the modest elevation in ELOVL5 tran-
script levels is unlikely to explain the reduced relative
sVLCFA levels in patient iPSCs. Other genes directly
involved in peroxisomal VLCFA catabolism were not dif-
ferentially expressed in patient relative to control fibro-
blasts or iPSCs. Regarding other hypotheses, it is
technically challenging to directly address cell prolifera-
tion rates and media uptake given the specialized condi-
tions required for the growth and maintenance of iPSCs
and their derivatives. As mentioned in our prior studies
[20], the lower sVLCFA levels in iPSC relative to fibro-
blast growth media could influence lipid profiles. The
MEF feeders in the iPSC media could as well; however,
the comparisons of control and patient cells were made
under the same growth conditions. Experiments using a
variety of controlled growth media could be useful to
further investigate the cell type specificity of aberrant
lipid levels in patient cells.
To further address the cell type specificity of lipid
metabolic defects, we determined relative PE plasmalo-
gen levels in fibroblasts, iPSCs, and NPCs from patients
and controls. We focused on cells with biallelic null mu-
tations in a given PEX gene since this should result in
marked plasmalogen deficiencies due to the crucial roles
peroxisome plays in plasmalogen biosynthesis [6–8]. In
agreement with these expectations, all such patient-
derived cells (fibroblasts, iPSCs, and NPCs) showed low
relative PE plasmalogen levels (Additional file 3). Patient
fibroblasts, iPSCs, and NPCs with partially functional
hypomorphic PEX gene alleles provided relative PE plas-
malogen levels generally consistent with prior reports of
the plasmalogen biosynthetic activity in the starting
fibroblast cultures [52–55]. Overall, the abnormalities in
relative sVLCFA levels observed in patient-derived cells
showed more striking cell type specificities than the cor-
responding abnormalities in relative PE plasmalogen
levels. This suggests that studies into the cell type speci-
ficity of other peroxisomal metabolic pathways, such as
bile acid and amino acid metabolism, may be warranted
in patient and control cells in the future.
Similar to our experiences with iPSCs from X-ALD pa-
tients [20], PBD-ZSD patient-derived iPSCs, but not fibro-
blasts, showed gene expression signatures consistent with
proposed mechanisms of pathogenesis. Most striking weregroups of DEGs enriched for organelle localization, espe-
cially those of mitochondrial function which tended to be
upregulated in patient iPSCs relative to controls. Although
mtDNA levels were consistent among all control- and
patient-derived fibroblasts (Fig. 3), they were variable
among all iPSCs, even different colonies from the same
donor. This is in general agreement with prior work show-
ing variation in mtDNA levels, and even mtDNA muta-
tion status, among iPSCs [74–76], with changes in
mtDNA content even reported according to the passage
number of a given iPSC colony [77]. Nevertheless, there
were no reproducible differences in mtDNA levels among
patient- and control-derived iPSCs. Future studies may
focus on mtDNA mutation status in patient-derived cells
and their changes according to passage number.
Historically, there have been numerous reports of
mitochondrial abnormalities in the peroxisome-deficient
mammalian cells [78–82]. More recently, the extent of
molecular cross-talk between mitochondria and peroxi-
somes has been increasingly appreciated. This has been
spurred on by the discovery of mitochondrial derived
vesicles (MDVs) that transport cargo to a subpopulation
of peroxisomes and lysosomes [83–86]. Although likely
to be complex, to date the only cargo known of MDVs
transported from mitochondria to peroxisomes is the
mitochondrial outer membrane protein MAPL [83–86].
We also note a body of literature linking mitochondrial
dysfunction with X-ALD [87–89].
Furthermore, DEGs showed enrichment for gene re-
lated to ER and Golgi function. There is a clear link be-
tween peroxisome and ER biology given the fact that
peroxisome arises from the ER through a de novo path-
way involving membrane budding [1]. Likewise, ER
stress has been observed in peroxisome-deficient cells
[78, 90–92]. The Golgi enrichment could reflect alter-
ations in cell trafficking and cellular communication that
would require further functional characterization. For
example, it is known that the ER, the Golgi, and the per-
oxisome are all involved in the generation of the lipid
portion of GPI-anchored proteins, which are associated
with lipid rafts [46]. Indirect evidence based on the clin-
ical phenotypes of individuals with mutations in genes
involved in GPI-anchor protein biosynthesis indicates
that GPI-anchor protein abnormalities can result in in-
tellectual disabilities [93].
In terms of future applications and directions, there
are numerous opportunities to improve patient-derived
models of PBD-ZSD and other diseases. For example,
targeted genetic modifications present an emerging
strategy for modeling age-related disease phenotypes in
cell culture [94]. iPSCs could also provide the basis for
co-culture models, especially those involving neurons
and OLs, or three-dimensional organoid models to in-
vestigate noncell autonomous processes relevant to
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we respect that it remains a challenge to generate
in vitro model systems for PBD-ZSD and other complex
disorders that involve multiple organ systems and pos-
sible gene–environment interactions.
Conclusions
The iPSCs reported herein complement PBD-ZSD patient-
derived fibroblast culture models and a diverse group of
animal models that have provided valuable insights into
the pathomechanisms of disease [96–100]. Patient-
derived iPSC models provide the unique advantages of
representing PEX gene mutations and possible modifier
genes in cell types most relevant to clinical phenotypes.
Our patient cohort includes a diverse spectrum of PEX
gene mutations with varying activity, including those
with two null PEX gene alleles and two hypomorphic
PEX gene alleles that confer partial function. This pre-
sents opportunities to evaluate mutation-specific ther-
apies (including nonsense suppressor drugs [101] and
molecular chaperones [18, 102] for individuals with the
common PEX1 p.G843D missense mutation) in relevant
cell populations. The multiple iPSC colonies we gener-
ated for each PBD-ZSD patient will help to minimize
confounding effects that extraneous genomic sequence
changes (conferred due to reprogramming) have on the
model system. We also note that patient-derived cell
models are not subject to species–specific differences in
peroxisome biology [103–105] that could confound the
evaluation of some targeted therapies. This is perhaps
best illustrated by differences in peroxisome prolifera-
tion observed in murine and human cells in response to
PPAR-alpha agonists [3].
Finally, the demonstration by GFP-PTS1 reporter as-
says that patient-derived neural and hepatic cell lineages
have impaired peroxisome assembly provides important
proof-of-concept that they could be used for quantitative,
cell-based, high-content screening (HCS) for compounds
that improve peroxisome assembly. Once optimized for
cell number and purity, iPSC-derived cells could be
used to build upon the success of a prior HCS study that
uncovered small molecules which improve peroxisome
assembly in PBD-ZSD patient fibroblasts [18]. Likewise,
we note the emerging role of iPSCs in toxicology assays
for potential liabilities of therapeutic agents [106] and
the possibility of uncovering environmental exposures
that could more severely impact patients with PBD-ZSD
and individuals with other diseases associated with per-
oxisomal dysfunction. In a broader context, the results
of HCS using PBD-ZSD patient-derived neural and hep-
atic cells could help address fundamental questions re-
garding the potential benefits of evaluating multiple
patient cell types in drug discovery efforts for a variety
of disorders.Additional files
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